Systematic Review
Copyright ©The Author(s) 2019.
World J Hepatol. Jul 27, 2019; 11(7): 596-606
Published online Jul 27, 2019. doi: 10.4254/wjh.v11.i7.596
Table 1 Management, prognosis and mortality in cirrhotic patients with spontaneous fungal peritonitis
StudyCountry, settingStudy designStudy populationManagement
Mortality
n (%)n (%)
Hwang et al[10], 2014South Korea, University HospitalRetrospective, Cross-sectionaln = 416 patients3rd generation cephalosporin (n = 15)In-hospital: -
SBP (n = 401)Antifungal: n = 5 (33.3%)1-mo: 11/15 (73.3%)
SFP (n = 4)Amphotericin B: n = 26-mo: 3/15 (20%)
Polymicrobial SFP (n = 11)Liposomal Amphotericin B: n = 1
Fluconazole: n = 2
Hassan et al[9], 2014Egypt, University HospitalProspective cohort studyn = 46 patientsNot describedIn-hospital: 1/3 (33.33%)
Control patients with no infection (n = 18)
SFP (n = 4; only 3 patients described with ascitic fluid polymorphs > 250 cells/mm3)
Karvellas et al[11], 2015(CATSS Database) from 28 medical centers in United States, Canada, Saudi ArabiaRetrospective cohort studyn = 126 patientsAnti-fungal: n = 9 (81.8%)In-hospital: 11/11 (100%)
SBP (n = 126)
SFP and SBP (n = 11)
Bremmer et al[1], 20151University of Pittsburgh, United StatesRetrospective, cross-sectional studyn = 25Antifungal: n = 15 (60%)In hospital: 15/25 (60%)
SFP (n = 25)One mo: 14/25 (56%)
Lahmer, et al[2], 2016University Hospital, GermanyRetrospective, cross-sectional studyn = 208 SFP (n = 20)Antibiotic pretreatment: SFP n = 17 Antifungal: n = 6 (30% of SFP)In-hospital: 18/20 (90%)
SBP (n = 28)
Gravito-Soares et al[6], 2017University of Coimbra, Coimbra, PortugalRetrospective, case–control studyn = 231Cefotaxime n = 2311 -mo: 4/8
SFP (n = 3)Antifungal: n = 5/8 (62.5%)(50%)
Polymicrobial SFP (n = 5)Fluconazole: n = 3
SBP (n = 119)Caspofungin: n = 1
Amphotericin B: n = 1